Mark your calendars for our virtual INVEST Precision Medicine conference, December 9-11
Here's a preview of some of the panel discussions at INVEST Precision Medicine, including diagnostics, investment trends, and building a bioinnovation hub.
Neonatal drug company charts course to commercialization
On the heels of winning an eight-year quest for approval of a drug to help preterm infants breathe, an East Coast drug developer outlined a $12 million to $13 million commercialization plan. Discovery Labs (NASDAQ:DSCO) secured approval from the U.S. Food and Drug Administration for Surfaxin, the first synthetic surfactant to treat respiratory distress syndrome […]
With the Rise of AI, What IP Disputes in Healthcare Are Likely to Emerge?
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
FDA approves first synthetic surfactant to help premature babies breathe
A drug for preterm infants born with respiratory distress syndrome has been approved by U.S. regulators. The neonatology drug developed by specialty biotechnology company Discovery Labs (NASDAQ:DSCO) is designed to treat the respiratory condition in which preterm infants are born without enough pulmonary surfactant, a substance made by the lungs needed for breathing, according to […]